

C. Expenditure during the year:

## **SCTAPPG Income and Expenditure**

Name of group: Sickle Cell & Thalassaemia APPG

Period covered by this statement: April 1 2021 – March 31 2022

£

A. Balance brought forward from previous year:	No funds were carried forward from previous year as the Society usually makes up the funds to carry out the project.	
B. Income received during the year:		
i. Membership subscriptions (parliamentarians)	0	
ii. Monetary donations (including external subscriptions and sponsorship)	Income made up of:  £10,000- Novartis £10,000 - Blue Bird Bio £12,773 - SCS Contribution	
iii. Trading income	0	
iv. Interest received	0	
v. Other (please explain)		
TOTAL income	32,773	





i. Employment costs (salaries, NI, pensions costs )	17,826
ii. Costs of contractors and freelance staff	12,061
iii. Visits and events (UK)	
iv. Visits and events (abroad)	
v. Cost of generating income	
vi. Office and communications costs	
vii. Other (please explain)	Overheads – 2,886
TOTAL expenditure	32,773
D. Balance carried forward ( A+ total B-total C)	0



E. Value of benefits in kind received from each source during the reporting year (in bands of up to £1,500; £1,501-£3,000; £3,001 to £4,500; £4,501 to £6,000 etc )

0

Please itemise according to the source and band

Pat Matadden

Signed by Chair of Group:

Date: 22<sup>nd</sup> June 2022



